Switching From Semaglutide to Tirzepatide: What to Discuss With Your Provider

Short answer: switching from semaglutide to tirzepatide is a decision and a dosing plan that only your prescriber can set. The two should not be taken together, and the labels do not give a standard conversion between them. This page lists why people consider it and what to ask.

Why people consider switching

• Progress has slowed or stalled on their current dose.
• Side effects are hard to tolerate.
• Trial data: in the SURMOUNT-5 head-to-head study, tirzepatide averaged 20.2% weight loss versus 13.7% for semaglutide at 72 weeks in adults with obesity, and averages do not predict any individual.
• Insurance coverage or cost changed.

What the labels say

The Zepbound label says using it together with other tirzepatide products or with any GLP-1 receptor agonist is not recommended. Neither label provides a dose-for-dose conversion from semaglutide to tirzepatide. That gap is why the timing and starting dose after a switch need to come from a prescriber, not from a chart or an online forum.

Questions to ask your prescriber

• Is switching appropriate for my situation, or should we adjust the current dose first?
• How long should I wait after my last semaglutide dose?
• What dose should I start at, and how will we step it up?
• How will we handle nausea and other side effects during the change?
• Will my insurance cover the new medication, and is prior authorization needed?

Reset your expectations

Even with a more effective medication, results build gradually and plateau. Trial averages describe groups, so your own experience may be faster or slower. Timelines from the calculator are estimates that can help frame what to expect.